LMA Protector vs I-Gel in Low-Flow Anesthesia for Laparoscopic Cholecystectomy
11 juli 2026 uppdaterad av: Ahmet Emre Akın, Fatih Sultan Mehmet Training and Research Hospital
Comparison of LMA Protector and I-Gel Use in Low-Flow Anesthesia for Laparoscopic Cholecystectomy: A Prospective Randomized Study
This prospective randomized study aims to compare two second-generation supraglottic airway devices (SGAs), the I-Gel and the laryngeal mask airway (LMA) Protector, in patients undergoing laparoscopic cholecystectomy under low-flow desflurane anesthesia.
The study evaluates the devices in terms of respiratory mechanics (dynamic compliance, peak inspiratory pressure, plateau pressure, and airway resistance), non-invasive perfusion parameters (oxygen reserve index, perfusion index, and pleth variability index), hemodynamic stability, ease of insertion, oropharyngeal leak pressure, and postoperative complication rates.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Sixty-two patients (ASA I-II, aged 18-65 years) scheduled for elective laparoscopic cholecystectomy were randomized into two groups: Group I (I-Gel) and Group P (LMA Protector).
General anesthesia induction was standardized, and maintenance was provided with desflurane at a fresh gas flow of 1 L/min to achieve low-flow anesthesia.
Peak inspiratory pressure (PIP), plateau pressure (Pplato), dynamic compliance (Cdyn), and airway resistance were recorded at six distinct intraoperative time points: 5 minutes after SGA insertion (T1), 1 minute after pneumoperitoneum insufflation (T2), 1 minute after the 30-degree reverse Trendelenburg position (T3), 10 minutes after insufflation (T4), 1 minute after desufflation (T5), and immediately before SGA removal (T6).
Oropharyngeal leak pressure (OLP) was measured after insertion and before removal.
Postoperative complications such as sore throat, cough, hoarseness, dysphagia, and nausea-vomiting were monitored postoperatively.
Studietyp
Interventionell
Inskrivning (Faktisk)
62
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Istanbul, Turkiet (Türkiye), 34752
- Fatih Sultan Mehmet Training and Research Hospital
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Patients aged 18-65 years
- American Society of Anesthesiologists (ASA) physical status I or II
- Scheduled for elective laparoscopic cholecystectomy
Exclusion Criteria:
- Known or predicted difficult airway or history of difficult intubation
- Body Mass Index (BMI) greater than 35 kg/m²
- High risk of gastroesophageal reflux or aspiration
- Severe cardiac, respiratory, renal, or hepatic disease
- Pregnancy
- Patient refusal to participate
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Group I: I-Gel
Patients managed with the I-Gel supraglottic airway device during low-flow desflurane anesthesia for laparoscopic cholecystectomy.
|
Placement of an appropriate size of i-gel supraglottic airway device for airway management during general anesthesia.
Anesthesia maintenance is provided with desflurane in a fresh gas flow of 1 L/min (low-flow anesthesia).
Andra namn:
|
|
Experimentell: Group P: LMA Protector
Patients managed with the LMA Protector supraglottic airway device during low-flow desflurane anesthesia for laparoscopic cholecystectomy.
|
Placement of an appropriate size of LMA Protector supraglottic airway device for airway management during general anesthesia.
Anesthesia maintenance is provided with desflurane in a fresh gas flow of 1 L/min (low-flow anesthesia).
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Dynamic Lung Compliance (Cdyn)
Tidsram: Measured intraoperatively at 6 specific time points from 5 minutes after device insertion until immediately before device removal.
|
Dynamic compliance of the respiratory system, calculated automatically by the ventilator as tidal volume divided by (peak inspiratory pressure minus positive end-expiratory pressure).
|
Measured intraoperatively at 6 specific time points from 5 minutes after device insertion until immediately before device removal.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Peak Inspiratory Pressure (PIP)
Tidsram: Measured intraoperatively at 6 specific time points from 5 minutes after device insertion until immediately before device removal.
|
Maximum airway pressure generated during the inspiratory phase, monitored to assess airway dynamics under general anesthesia.
|
Measured intraoperatively at 6 specific time points from 5 minutes after device insertion until immediately before device removal.
|
|
Plateau Pressure (Pplateau)
Tidsram: Measured intraoperatively at 6 specific time points from 5 minutes after device insertion until immediately before device removal.
|
Pressure applied to the small airways and alveoli during a period of zero gas flow, monitored to assess risk of barotrauma.
|
Measured intraoperatively at 6 specific time points from 5 minutes after device insertion until immediately before device removal.
|
|
Airway Resistance
Tidsram: Measured intraoperatively at 6 specific time points from 5 minutes after device insertion until immediately before device removal.
|
The resistance of the respiratory tract to airflow during mechanical ventilation, calculated using peak and plateau pressures.
|
Measured intraoperatively at 6 specific time points from 5 minutes after device insertion until immediately before device removal.
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Samarbetspartners
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
1 juli 2020
Primärt slutförande (Faktisk)
31 oktober 2020
Avslutad studie (Faktisk)
31 oktober 2020
Studieregistreringsdatum
Först inskickad
5 juli 2026
Först inskickad som uppfyllde QC-kriterierna
11 juli 2026
Första postat (Faktisk)
16 juli 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
16 juli 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
11 juli 2026
Senast verifierad
1 juli 2026
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- FSM KAEK-2020/79
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .